{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_names_name in Any Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2004)
Source URL:
First approved in 2004
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
First approved in 2003
Source:
21 CFR 349
Source URL:
Class:
POLYMER
Polidronium Chloride is a biocide agent which can be used as a preservative, unique in its high safety profile. Polidronium Chloride is a polycationic preservative that, unlike benzalkonium chloride, does not have detergent properties. This agent complies with both the US and European Pharmacopeia guidelines for preservative efficacy. Polidronium Chloride is a large molecule that preferentially targets microorganisms and produces minimal toxicity towards mammalian cells. Polidronium Chloride compares favorably to other preservatives in terms of efficacy. Published studies demonstrate that this preservative, added to contact lens solutions, artificial tears, and ocular hypotensive drops may offer benefits in terms of ocular tolerability compared to benzalkonium chloride. Polidronium Chloride is comparable in tolerability to other alternative preservatives such as sodium perborate, Purite. Therefore, Polidronium Chloride may be considered as a viable alternative to benzalkonium chloride for many topical ophthalmic formulations.Polidronium Chloride prepared by the controlled polymerization of dimethylamine and bis-dichlorobutene, end capped with tris-beta-hydroxyethylamine.
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2001)
Source URL:
First approved in 2001
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
First approved in 1996
Source:
NDA021753
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2017)
Source URL:
First approved in 1994
Source:
21 CFR 341
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NDA215390
(1999)
Source URL:
First approved in 1988
Source:
ANDA212506
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NDA207947
(2015)
Source URL:
First approved in 1981
Source:
ANDA086183
Source URL:
Class:
POLYMER
Status:
Investigational
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00397943: Phase 2 Interventional Completed Tuberculosis
(2006)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE